VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 333 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2016. The put-call ratio across all filers is 1.34 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2018 | $1,686,000 | -61.9% | 105,920 | -65.7% | 0.07% | -58.9% |
Q3 2017 | $4,420,000 | +139.6% | 308,500 | +189.1% | 0.18% | +125.0% |
Q2 2017 | $1,845,000 | -47.4% | 106,704 | -66.4% | 0.08% | -47.4% |
Q1 2017 | $3,506,000 | -3.2% | 317,899 | +27.4% | 0.15% | -29.6% |
Q4 2016 | $3,621,000 | +4.8% | 249,435 | +77.3% | 0.22% | -7.7% |
Q3 2016 | $3,454,000 | -55.5% | 140,719 | -63.5% | 0.23% | -54.9% |
Q2 2016 | $7,769,000 | +17.7% | 385,788 | +53.7% | 0.52% | -1.3% |
Q1 2016 | $6,600,000 | -67.3% | 250,955 | +26.2% | 0.53% | -66.8% |
Q4 2015 | $20,207,000 | +523.7% | 198,799 | +994.2% | 1.58% | +564.7% |
Q3 2015 | $3,240,000 | +64.8% | 18,168 | +105.3% | 0.24% | +44.2% |
Q2 2015 | $1,966,000 | +159.0% | 8,851 | +131.4% | 0.16% | +87.5% |
Q1 2015 | $759,000 | -66.0% | 3,825 | -75.5% | 0.09% | -67.5% |
Q4 2014 | $2,234,000 | – | 15,613 | – | 0.27% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |